Published in final edited form as:

Cancer Res. 2019 February 01; 79(3): 423–436. doi:10.1158/0008-5472.CAN-18-1805.

A blazing landscape: Neuroinflammation shapes brain metastasis

Hila Doron¹, Tobias Pukrop², and Neta Erez^{1,*}

¹Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel

²Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, Regensburg, Germany

Abstract

Brain metastases are more common than primary CNS tumors, and confer grave prognosis on patients, as existing treatments have very limited efficacy. The tumor microenvironment has a central role in facilitating tumorigenesis and metastasis. In recent years, there has been much progress in our understanding of the functional role of the brain metastatic microenvironment. In this review we discuss the latest advances in brain metastasis research, with special emphasis on the role of the brain microenvironment and neuroinflammation, integrating insights from comparable findings in neuropathologies and primary CNS tumors. In addition, we overview findings on the formation of a hospitable metastatic niche, and point out the major gaps in knowledge towards developing new therapeutics that will co-target the stromal compartment, in an effort to improve the treatment and prevention of brain metastases.

Introduction

Brain metastases are one of the deadliest forms of tumor metastasis. Arising in 10-30% of adult patients with systemic malignancies (1), brain metastases confer dismal prognosis, with a median survival of less than one year (Figure 1A) (2,3). The main cancer types that frequently metastasize to the brain are lung, breast, melanoma, renal and colorectal cancers (2). Different studies suggest that the incidence of brain metastasis is twice to ten times higher than primary central nervous system (CNS) malignancies (e.g. glioma) (4,5). Interestingly, post-mortem studies suggest higher incidence of brain metastases compared with clinically diagnosed incidence (6). Moreover, the incidence of brain metastasis appears to be on the rise (7). Possible explanations for this apparent increase include better diagnosis of smaller, asymptomatic brain metastasis by MRI, and improved control of extracranial disease by systemic therapy, enabling the emergence of otherwise not clinically manifested metastasis (1,6).

When discussing brain metastases, it is important to keep in mind that they are not a single clinical entity: major differences in the diagnosis, treatment and prognosis depend on various

*Correspondence: Neta Erez, Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. netaerez@tauex.tau.ac.il Tel.: +972-3-6408689.

Disclosure of Potential Conflicts of Interest: No potential conflicts of interest.

parameters including the primary tumor from which metastases developed, suitability for targeted therapies, number of metastases, stage of extra-cranial disease etc. Brain metastasis from different primary tumors can occur early in the clinical course of the disease, at the time of initial diagnosis (synchronous), or sometimes months or years after surgical removal of the primary tumor (metachronous). The currently used diagnosis-specific graded prognostic assessment (DS-GPA) of patients with brain metastases are associated with tumor-specific parameters: The DS-GPA for non small cell lung carcinoma (NSCLC), breast cancer and malignant melanoma includes molecular predictive markers, such as EGFR, Her2 and B-Raf, respectively, to identify subgroups with a significantly improved overall survival (OS) (8–10). For example, patients with the best melanoma molecular markers (mol-GPA) score have an estimated OS of 34.1 months compared with 7.1 months in the past (8). In addition to molecular subgroups, the OS of patients with brain metastasis also correlates with the infiltration pattern of macrometastases at the brain parenchyma/metastatic interface: while metastases of renal cell cancer are mainly non-infiltrative and are additionally protected by a highly vascularized collagen capsule, the majority of NSCLC brain metastases infiltrate into the adjacent brain parenchyma with tumor cell cohorts, and malignant melanoma cells favor an angio-cooptive infiltration (11). In general, an infiltrative phenotype is associated with a poor prognostic outcome (11). However, the underlying mechanisms that differentiate patterns of brain metastatic infiltration are poorly understood.

In brain metastasis, earlier studies identified gene signatures in primary breast cancer cells that were associated with brain tropism (12), while a more recent study demonstrated branched evolution that distinguishes the mutation landscape in the primary tumor from its brain metastases (13). Thus, additional co-evolution with the brain microenvironment may be required to enable brain colonization by disseminated metastatic cells. There is a growing understanding that the metastatic microenvironment plays a crucial role in enabling brain tropism and colonization of disseminated tumor cells. Herein, we summarize the main findings of recent pre-clinical studies focused on the biology of the brain metastatic microenvironment, with emphasis on the role of neuroinflammation.

The brain microenvironment

Reciprocal interactions between cancer cells and the microenvironment were shown to contribute to tumor progression and to organ-specific metastasis (14–17). The brain harbors a unique microenvironment: the *macroglia* cell population which is composed of 75.6% *oligodendrocytes* and 17.3% *astrocytes* and the *microglia* that represent 6.5% of the non-neuronal cells (18). The brain microenvironment also includes endothelial cells, pericytes, ependymal cells, resident and infiltrating immune cells, and other cell types, which play a crucial role in maintaining physiological homeostasis by communications with neurons (Box 1, Figure 1B) (18).

Similarly to other organs of the body, cells in the microenvironment of the brain can sense and respond to danger signals induced by pathogen invasion or tissue damage, resulting in instigation of neuroinflammation (19). This physiological response in the brain microenvironment is reminiscent to changes that occur in the brain metastatic niche, as will be discussed herein. Notably, pre-clinical studies of brain metastasis and of the interactions

of metastatic tumor cells with the microenvironment mostly rely on murine models. While all models entail certain limitations (Box 2), they nevertheless provide important insights on metastatic extravasation, invasion into the brain parenchyma, growth in the brain, interactions with the microenvironment and therapeutic responses.

Neuroinflammation in brain metastasis

Neuroinflammation in the CNS is instigated in response to damage signals. Cells in the brain parenchyma can sense and respond to danger signals resulting from pathogen invasion (pathogen-associated molecular patterns=PAMPs) or tissue damage (damage-associated molecular pattern = DAMPs). In the first-line of response DAMP-/PAMP-signals rapidly activate the adjacent astrocytes and microglia (45). This locally circumscribed first line of glial response is very potent in the defense from pathogenic intruders or in repairing tissue damage without recruiting other cell types. Thus, astrocytes and microglia are central in regulating the CNS homeostasis and tissue repair. However, if this first line of defense is not effective or the damage/affected area is too large, then full blown neuroinflammation develops. This is characterized by enhanced secretion of cytokines and chemokines, persistent activation of astrocytes and microglia, increased blood vessel permeability and recruitment of immune cells (46,47). Knowledge on the instigation and regulation of neuroinflammation mainly originated in studies of neurological diseases and CNS injuries (19,48). Dysregulation of these pathways leads to uncontrolled damage response, which contributes to the pathology of neurodegenerative diseases (49), exacerbates vascular injury following stroke (50), drives autoimmune diseases (51), and facilitates primary CNS tumors (52).

Many of the changes described in the brain metastatic microenvironment are reminiscent of these dysregulated tissue damage responses, including permeability of the blood-brain barrier (53), instigation of astrogliosis and neuroinflammation (54), and recruitment of leukocytes (55), which in turn collectively facilitate metastatic growth of invading cancer cells (25,56). Therefore, findings from these fields may help us understand the roles of cellular brain components at various phases of brain metastasis. These parallels suggest that the physiological tissue damage response in the brain is hijacked during colonization by metastatic cells, and neuroinflammation is recently emerging as a promising direction to uncover processes associated with the development of brain metastases (57–59).

Astrocytes in neuroinflammation

Activation of astrocytes in response to tissue damage is termed ‘astrogliosis’. It is characterized by upregulation of the cytoskeletal glial fibrillary acidic protein (GFAP), upregulation of pro-inflammatory genes (60), and identified by the formation of a ‘gliotic scar’: reactive astrocytes with elongated processes that form a physical and functional wall around demarcated brain lesions (61). Astrogliosis has neuroprotective functions that support neuronal recovery during the acute phase, but may entail detrimental inflammatory responses that induce further tissue damage (62). Astrogliosis is also evident in brain metastases: astrocytes surround and infiltrate brain metastases in mice, and are recruited to

the brain-metastases interface in human brain metastases (57,59,63), and therefore the complex interactions between astrocytes and tumor cells are a topic of intense research.

Pro-inflammatory signaling in astrocytes was shown to be activated by lung cancer cell-derived factors such as macrophage migration inhibitory factor (MIF), interleukin-8 (IL-8) and plasminogen activator inhibitor-1 (PAI-1) in co-culture experiments (64). Once activated, astrocytes secrete TNF- α , interleukin-6 (IL-6), and interleukin-1 β (IL-1 β). Such pro-inflammatory activation of astrocytes stimulated *in vitro* proliferation of lung cancer cells (64). While the molecular players may vary, inflammatory activation of astrocytes seems to be a general feature of brain metastasis: melanoma cell-secreted factors induced IL-23 expression in astrocytes, leading to enhanced transendothelial migration of melanoma cells *in vitro* (65). Notably, astrocytes also express IL-23 during autoimmune diseases, such as multiple sclerosis (MS) (66). In breast cancer, tumor cell-derived IL-1 β activated JAG1 signaling in astrocytes, which in turn promoted cancer stem cell (CSC) self-renewal *in vitro*, and experimental brain metastasis *in vivo*. Brain metastasis-free survival in breast cancer patients correlated with lower expression of IL-1 β , suggesting clinical relevance of these findings (67). Similarly, secretion of MMP-1 and COX-2 by brain-metastasizing breast cancer cells induced expression of CCL7 by activated astrocytes, which in turn promoted BBB permeability and experimental brain metastasis *in vivo* (68). These findings implicate the importance of pro-inflammatory signaling by astrocytes to promote multiple aspects of brain metastasis. However, the functional role of specific cytokines and chemokines that were identified in co-culture studies should be further evaluated *in vivo*.

Induction of neuroinflammation was shown to precede macrometastases: brains bearing spontaneous melanoma micrometastases already express higher levels of the inflammatory mediators CCL17, CCL2 and CXCL10 (37). Notably, CXCL10 was also shown to be expressed by astrocytes in Alzheimer's disease in association with senile plaques (69), and in response to LPS exposure and stroke (60). These findings implicate stromal cell-derived CXCL10 in neuroinflammation, as well as in the formation of brain metastasis. Similarly, CCL17, shown to be expressed by microglia in Alzheimer's disease (70), is upregulated in brains of mice inoculated with Vemurafenib-resistant melanoma cells (71). This may implicate stromal cell-derived CCL17 in supporting chemoresistance to BRAF inhibitors. The parallels of inflammatory mediators in brain pathologies and in brain metastasis suggest that canonical neuroinflammatory pathways are hijacked by tumor cells to promote metastases formation and growth.

The mechanisms by which astrocytes are activated by tumor cells are still largely unresolved. The close proximity between astrocytes and tumor cells, resulting from astrogliosis, implicates reciprocal paracrine signaling as a main communication route (37,65,67,72–75). Assembly of carcinoma-astrocyte gap junctions composed of connexin 43 (Cx43), resulting in pro-inflammatory activation of astrocytes, enhanced resistance of tumor cells to chemotherapy *in vitro* and *in vivo* (76–78). This interaction may represent another aspect of cancer-induced astrogliosis and gliotic scar formation, physically 'bridging' between astrocytes and tumor cells. Once recruited and activated by brain metastasizing cells, astrocytes induce growth-promoting signaling in tumor cells (76,79).

The reciprocal interactions of tumor cells and astrocytes were also shown to contribute to chemoresistance and tumor cell survival due to upregulation of GASTA5, BCL2L1 and TWIST1 expression in cancer cells *in vitro* (77). Other studies demonstrated that bidirectional interactions between astrocytes and breast cancer cells support chemoresistance via activation of the endothelin axis (80). Blocking this pathway with an antagonist of the endothelin receptor was beneficial in the treatment of breast and lung cancer experimental brain metastases (81). Interestingly, the initial response of astrocytes to brain invasion by tumor cells was suggested to be anti-tumorigenic: astrocytes were shown to induce tumor cell apoptosis via plasmin-activator (PA) secretion. Secretion of Serpins (PA inhibitors) by tumor cells prevented apoptosis and increased vascular co-option in experimental brain metastasis (73). Thus, while the early response of astrocytes to brain invasion by tumor cells may be anti-tumorigenic, growth-promoting mechanisms eventually prevail, and enable metastatic growth.

Microglia in neuroinflammation

Microglia are important mediators of the brain response to tissue damage (82), and are similarly activated at the tumor-brain interface in brain metastasis (83,84). Immunohistochemical analysis of microglia in human brain metastases of NSCLC, breast cancer and melanoma indicated intense microglia activation with evident peritumoral accumulation and intratumoral infiltration (85). Thus, the localization of microglia is reminiscent of the gliosis response to traumatic brain injury sites, at the interface between normal and damaged brain tissue (86).

Pro-inflammatory signaling in microglia was shown to be instigated following lipopolysaccharide (LPS) injection, including expression of TNF- α , iNOS, and IL-6 (87). Moreover, targeting of activated microglia/macrophages was shown to reduce tumor growth in a model of intracranial injection of breast cancer cells (84). Microglia were also shown to facilitate invasion of metastatic breast carcinoma cells in an organotypic *ex-vivo* brain slices model (88). This pro-invasive function of microglia could be inhibited by microglia depletion, by the WNT-inhibitor Dickkopf-2, by LPS-treatment or by CXCR4 inhibition, indicating the molecular pathways involved (82,88,89). Moreover, similarly to the role of the PI3K γ pathway in mediating immune suppression by tumor-associated macrophages (TAM) in primary breast tumors (90), a recent study demonstrated the activation of PI3K in patients with breast cancer brain metastases, and identifies its function as a master regulator of the metastasis-promoting function of microglia (Blazquez et al. *Glia*, *In Press*).

Findings from primary brain malignancies and from brain metastasis indicate that the metastasis-promoting functions of microglia phenotype are induced by tumor cells (91–93). Interestingly, astrocytes were also shown to modulate the recruitment of microglia to brain metastasis *in vivo* (94), adding another dimension to the complex neuroinflammatory networks that facilitate metastasis. However, while in neurodegenerative pathologies astrocytes and microglia were demonstrate to interact reciprocally in mediating inflammatory responses that contribute to disease progression (95,96), surprisingly little is known about the molecular factors that underlie the role of microglia in brain metastasis, and their crosstalk with astrocytes.

Recruited immune cells

Recruited macrophages and T cells are a prominent feature of neuroinflammation and brain metastasis. However, in most studies there is no clear distinction between resident microglia and recruited macrophages regarding identification and function. A study utilizing multi-transgenic mouse models that enable ontology tracing, demonstrated that bone marrow-derived macrophages are recruited into primary brain tumors (glioma) and to experimental brain metastases, where they are reprogrammed to express distinct inflammatory gene signatures (91). These findings are supported by a study that demonstrated *in vitro* functional differences between microglia and monocyte-derived macrophages in facilitating tumor cell invasion, evident by their response to CSF-1R blockade (89).

Macrophages were shown to infiltrate into experimental breast cancer brain metastases, and to enhance tumor cell invasion and colonization via secretion of Cathepsin S (97). Intracranially implanted breast cancer cells were demonstrated to express high levels of Lymphotoxin β , which propelled the polarization of infiltrating macrophages towards a tumor-promoting M2-like phenotype (98), suggesting that metastases-recruited macrophages may function in promoting an immunosuppressive brain microenvironment. Macrophages were also shown to induce breast cancer cell invasion into the brain via CSF-1 secretion (89). Interestingly, targeting macrophages in a model of primary CNS malignancy (glioma) resulted in blockade of tumor progression (92).

T cells were also implicated in brain colonization. In intracranial injections of melanoma, breast and colon cancer cells into mice, regulatory T cells (Tregs) were shown to infiltrate cancerous lesions and to mediate immunosuppression (99). In human brain metastasis T cells are found mainly at the interface of the brain parenchyma/brain metastases tissue and in the metastatic stroma. Several studies suggested that CD3⁺ T cells may play a functional role in the microenvironment of brain metastasis. Moreover, while the density of regulatory T cells is not correlated with prognosis, high density of CD3⁺ or CD8⁺ T cells was shown to be correlated with better OS (57,100). A study of experimental melanoma brain metastasis in mice reported a similar infiltration pattern, where most of the CD3⁺ T cells were CD4⁺ rather than CD8⁺ lymphocytes (85). Interestingly, the infiltration of the effector T cells was suggested to be facilitated by the presence of extracerebral tumor lesions, which activated the endothelial cells of the blood-brain barrier to enhance leukocyte trafficking into brain metastases (101). Taken together, these findings implicate the adaptive immune system in brain metastasis and suggest that immunotherapy could be a promising therapeutic avenue for the treatment of brain metastasis, as discussed below. However, the recruitment, trafficking, functions and activation of T cells in the microenvironment of brain metastases are still largely unresolved.

Thus, activation of brain stromal cells and recruited immune cells orchestrates neuroinflammation and facilitates metastatic growth. These observations support co-targeting of both tumor cells and the inflammatory stroma in brain metastases.

The blood-brain barrier (BBB) and neuroinflammation in brain metastasis

Brain metastasizing cancer cells initially encounter the BBB, a highly specialized vascular structure which selectively controls the blood flow and its contents into the brain (53). The BBB is composed of endothelial cells connected by tight junctions, pericytes and the end-feet of astrocytes which surround the basement membrane of blood vessels, effectively limiting passive paracellular permeability. In addition to this physical barrier, the BBB contains active molecular transport systems (102), that impair CNS drug delivery. Importantly, the BBB is also central in regulating the recruitment and trafficking of peripheral immune cells into the brain. For example, brain endothelial cells express abluminally CXCL12, the ligand for CXCR4, to prevent CXCR4 expressing leukocytes from infiltrating the brain parenchyma under normal conditions (103). Similarly, the astrocyte end-feet express the death ligand CD95L, which under physiological conditions leads to T cell apoptosis (104). Therefore, under normal conditions, the BBB also functions as an immunological barrier. During active neuroinflammation, T cells and myeloid cells enter the brain mainly via post-capillary venules and their infiltration requires not only transmigration of the endothelial cells, but also overcoming the glia limitans (see Box 1, Figure 1B). This is enabled during neuroinflammation by activation of brain endothelial cells and downregulation of immunological barrier molecules on perivascular cells, to permit the entry of peripheral immune cells to the brain parenchyma. However, very little is known about the regulation of immune cell infiltration via the BBB in the context of brain metastases.

Following extravasation in the brain, tumor cells may outgrow, or remain dormant. Findings from mouse models of experimental brain metastasis of breast cancer (105) and melanoma (106) demonstrated that tumor cells were predominately positioned along the abluminal surfaces of microvessels in the perivascular space, suggesting that co-option of blood vessels in the brain and initial growth on the inner basement membrane is a central mechanism during the early growth of brain disseminated cells. Notably, the initial interactions with the brain perivascular niche may also affect dormancy, as suggested by pre-clinical imaging studies in mice, that detected brain metastasizing cancer cells (from lung, breast cancer and melanoma) in a dormant state at the perivascular niche in the brain (107–109). The specific mechanisms of vessel interactions and vascular co-option depend on various molecules, and may be fostered via adhesion with integrin beta-1 (105), and expression of L1CAM by brain metastasizing cancer cells (73,106). Clinical evidence from patients with melanoma brain metastasis suggested that initial metastatic growth along blood vessels is operative also in human brain metastasis (105). Interestingly, astrocytes and perivascular macrophages, which are part of the BBB, may be involved in this process: a study using various breast cancer cell lines showed that astrocyte-derived HGF induced c-MET activation in tumor cells, which in turn enhanced adhesion to endothelial cells (110). Taken together, these findings link astrocytes and microglia as part of the BBB, with tumor cell extravasation, dormancy and immune cell trafficking (Figure 1B).

The brain-tumor barrier (BTB)

The BTB is the vascular system around and within CNS tumors and brain metastases. Permeability of the BTB is a subject of debate; some studies suggested that impaired BBB

and permeable BTB are hallmarks of brain metastasis (53). Conversely, other studies in various mouse models of brain metastasis (including breast cancer and melanoma), reported that the permeability of the BTB is vastly heterogeneous, and is not well correlated with metastatic growth rate (111–114). Interestingly, quantitative fluorescence microscopy in pre-clinical tumor models of glioma compared with brain metastasis of breast cancer, reported that glioma-associated vasculature is more permeable than the vasculature in brain metastases (115).

Increased BBB permeability was shown to be an early event, associated with the formation of spontaneous brain micrometastases in mice (37). Increased permeability may also be part of the instigated neuroinflammation in the metastatic microenvironment. CCL2 upregulation in cancer cells resulted in increased transendothelial migration of small cell lung carcinoma (SCLC) (116).

Moreover, endothelial cells are active mediators of pro-inflammatory signaling that facilitates increased BBB permeability and enhanced invasion capacity of tumor cells: secretion of tumor necrosis factor- α (TNF- α) by brain endothelial cells induced by tumor cell-secreted substance P, augmented breakdown of the BBB and colonization of breast cancer cells in brain by modifying the localization and distribution of tight junctions on brain endothelial cells (117). A study on breast cancer brain metastasis showed that VEGF secretion from breast cancer cells induced activation of inflammatory STAT3 signaling in endothelial cells. STAT3 inhibition resulted in decreased invasion of breast cancer cells to brain, and suppression of angiogenesis and metastasis (118). These studies suggest that pro-inflammatory signaling contributes to increased BBB permeability thus enhancing tumor cell invasion into the brain.

In this context, it is important to ask whether modifying the brain vessel permeability has therapeutic potential. While at early stages enhanced permeability may contribute to metastatic invasion, selectively increasing the BTB permeability in overt brain metastasis was suggested to improve efficacy of therapeutic targeting in a mouse model of brain metastasis (119). In clinical studies, whole brain radiation therapy for brain metastasis was reported to result in increased BBB permeability in patients with brain metastases from NSCLC (120). However, future studies are required to better elucidate the interplay between neuroinflammation, BTB permeability and improved therapeutic delivery and efficacy of drugs to treat brain metastases.

The brain microenvironment and targeted therapeutics

Most chemotherapies, targeted therapeutics and immunotherapy that are routinely used systemically to treat metastatic disease are often less effective in treating brain metastases from solid tumors. The brain microenvironment is an important determinant in the response to systemic therapeutics, and was shown to actively mediate resistance to chemotherapy in multiple *in vitro* and *in vivo* mouse studies (77,80,121).

Pre-clinical testing of microenvironment-targeted therapeutics resulted in some promising outcomes. For example, targeting of Cathepsin S, secreted by both tumor cells and

macrophages reduced experimental brain metastasis of breast cancer (97) and co-targeting of tumor cells and VEGF receptor-2 inhibited growth of breast cancer xenografts in brain (122). In clinical trials, targeting VEGF-A with bevacizumab was tested in combination with WBRT in patients with brain metastases from various solid tumors, but did not prove to be effective (123), and a first-in-human clinical trial with BLZ945, a drug targeting CSF-1R, is ongoing for metastatic solid tumors ([Clinicaltrials.gov](https://clinicaltrials.gov)). Pre-clinical studies also showed that co-targeting astrocytes using macitentan, an antagonist of the endothelin receptors, was beneficial in experimental brain metastasis of lung and breast cancers (81,124). The results from pre-clinical studies emphasize the potential advantages of therapeutic combinations that include targeting of the brain microenvironment (Table 1). Nevertheless, data on the benefits of microenvironment-targeted therapeutics in brain metastases is very limited, as most clinical trials of targeted therapeutics are focused on molecules expressed by cancer cells (125,126).

Immunotherapy for treatment of brain metastasis

The approval of immunotherapeutic strategies and immune checkpoint blockade dramatically changed the landscape of treatment strategies for several cancer types, in particular melanoma, non-small cell lung carcinoma (NSCLC), and renal cell carcinoma (127), which have a high rate of brain metastasis. Brain metastases originating in tumors with a high mutagenic load (such as melanoma and lung cancer) are likely to be better candidates for immune checkpoint therapy. Indeed, immune checkpoint inhibition with monoclonal antibodies targeting the cytotoxic T-lymphocyte antigen 4 (Ipilimumab, anti-CTLA-4) and antibodies that target the programmed cell death protein 1 (Nivolumab, Pembrolizumab, anti-PD-1) have revolutionized the treatment of metastatic melanoma (128).

Findings of T cell composition and infiltration in patients with brain metastasis suggest that these considerations may be relevant also to brain metastatic relapse: while some patients have very little TILs in brain, high density of CD3⁺ or CD8⁺ T cells correlated with better OS (100,129). Notably, expression of the PD-1 ligand (PD-L1) was demonstrated in human specimens of brain metastases from melanoma (130) and breast cancer (129), and correlated with higher density of tumor-infiltrating lymphocytes expressing PD-1, suggesting that upregulation of immune checkpoints may be important for the ability of brain metastases to evade the immune system and enhance immunosuppression.

In this context, it is also important to consider the role of myeloid derived suppressor cells (MDSCs), immature myeloid cells with suppressive activity on T cells via immune checkpoint signaling. While not much is known about MDSCs in brain metastasis, they were implicated in immune suppression in neuroinflammatory diseases (131) and their infiltration to human glioblastoma tumors was associated with reduced TILs in brain lesions (132). Moreover, blockade of MDSCs was suggested to be beneficial in combination with immune checkpoint treatment in mouse models of glioblastoma (133), and in prevention of brain metastasis (134) suggesting that MDSC blockade should be considered also in immunotherapy of human brain metastasis.

Patients with brain metastasis were previously excluded from clinical trials with immune checkpoint inhibitors, limiting the available knowledge on the efficacy of

immunotherapeutics for brain metastasis. However, several recent clinical studies performed in melanoma or in NSCLC patients with active brain metastases that were treated in monotherapy or in combination of both checkpoint inhibitors, demonstrated benefit on OS of double checkpoint blockade (135–140), and multiple other studies are ongoing (141). Notably, the beneficial effects of anti-CTLA-4 and anti-PD1 on brain metastasis may be mediated in part by sustained systemic effects on activated T cells that infiltrate the brain and engage in anti-tumor responses. This is supported by a recent pre-clinical study demonstrating that efficient immune checkpoint inhibition for the treatment of intracranial melanoma depended on systemic activation of CD8⁺ T cells and enhancement of their recruitment to the brain (101). Additional clinical findings, as well as pre-clinical mechanistic studies are required to investigate the efficacy, and provide the rationale for immune checkpoint blockade in the treatment of brain metastasis.

Radiotherapy, a standard therapy approach for CNS tumors and brain metastasis, was shown to induce immunostimulatory effects that may be therapeutically beneficial, including downregulation of immunosuppressive cytokines, enhanced immune cell recruitment, and increased cytotoxic T lymphocyte (CTL) efficacy (142). These effects on activation of the immune response result, at least partially, from radiation-induced tissue damage and necrosis. However, radiotherapy was also demonstrated to enhance the expression of PD-L1 in tumor cells and in antigen-presenting cells in a mouse model of breast cancer, suggesting that it may also have immunosuppressive effects (143). Importantly, recent pre-clinical and clinical studies which assessed the combination of radiotherapy with immunotherapy found potential synergism between these two treatment modalities (142,144). While these results still need to be validated in larger studies, the data suggest that combining radiotherapy with immune checkpoint blockade may prove to be beneficial in targeting the metastatic microenvironment to combat brain metastases.

Conclusions and future perspectives

The incidence of brain metastasis is rising and survival remains very poor. Therefore, there is an acute need to define mechanisms and test novel therapeutic approaches for brain metastasis. The accumulated knowledge gained in past years from the studies discussed here clearly indicate that reciprocal interactions between tumor cells and brain stromal cells are a driving force of brain metastasis. This is mediated partially by hijacking of physiological tissue damage response and immune cell trafficking pathways in the brain microenvironment, and subsequent induction of local neuroinflammation around the metastatic lesion (Figure 2).

Studying the metastatic niche and mechanisms that sustain dormancy are promising approaches towards uncovering the earliest stages of metastasis. Understanding the early events that precede the formation of brain macrometastases will greatly advance our ability to design more efficient therapeutics. Future studies aimed to promote this characterization should focus on elucidating the tumor-derived and stromal cell-derived factors that govern the instigation of neuroinflammation and vascular changes at the pre-metastatic niche. To facilitate this research direction, development of novel pre-clinical models of brain metastasis that will include genetic tools for specific targeting of candidate factors is

required (some available experimental and genetic tools are summarized in Table 1 and Table 2, respectively). Moreover, since recent studies suggest that the operative mechanisms in micrometastases may be different than the ones operative in full-blown brain macrometastases (145), experimental tools that enable this distinction are also needed.

Clinical targeting of brain metastases formation at early stages will only be feasible if diagnostic tools for patient stratification are available. This may include identification of predictive biomarkers that will reflect changes in the brain microenvironment (e.g. circulating inflammatory proteins, circulating DNA, and tumor-derived extracellular vesicles), or the presence of disseminated tumor cells. Such markers could potentially be identified in liquid biopsies of blood and/or CSF, and allow personalized design of treatment approaches following removal of primary tumors, to monitor progression to systemic disease.

Another major limitation of developing more efficient tools for early, preventive targeting of brain metastasis is the efficiency of imaging modalities (146). Insights from pre-clinical models of the early stages can be applicable to human disease only if available imaging methods will enable earlier diagnosis, in patients with yet asymptomatic brain metastatic lesions. Further studies are also needed to thoroughly characterize cancer type-specific responses of the brain metastatic microenvironment, as well as unifying mechanisms that are common to the brain response during brain metastasis originating from different tumors, in order to test their applicability as therapeutic targets.

While knowledge from pre-clinical studies on the brain metastatic microenvironment is emerging, data from clinical studies on microenvironment targeting in the treatment of brain metastasis therapy is still limited. Hopefully, in the coming years we will see integration of the pre-clinical findings described in this review into the design of novel clinical strategies aimed at prevention and better treatment of brain metastasis.

Acknowledgments

The authors would like to thank Malak Amer and Dr. Raquel Blazquez for critical reading of the manuscript.

Grant Support

NE is supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 637069 MetCAF), The Israel Cancer Research Fund (ICRF), and the Israel Cancer Association (ICA). TP and NE are supported by The German Research Foundation (DFG PU 355/4-1). TP is supported by the The German Research Foundation (DFG FOR2127 PU 355/5-1).

References

1. Loeffler, JS. Epidemiology, clinical manifestations, and diagnosis of brain metastases UpToDate. Wen, PY, editor. UpToDate; Waltham, MA: [Accessed on November 27, 2016]
2. Berghoff AS, Schur S, Fureder LM, Gatterbauer B, Dieckmann K, Widhalm G, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. *ESMO Open*. 2016; 1(2):e000024. [PubMed: 27843591]
3. Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. *Neuro Oncol*. 2017; 19(11):1511–21. [PubMed: 28444227]

4. Ekici K, Temelli O, Dikilitas M, Halil Dursun I, Bozdogan Kaplan N, Kekilli E. Survival and prognostic factors in patients with brain metastasis: Single center experience. *J BUON*. 2016; 21(4): 958–63. [PubMed: 27685920]
5. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. *J Neurooncol*. 2005; 75(1):5–14. [PubMed: 16215811]
6. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. *Curr Oncol Rep*. 2012; 14(1):48–54. [PubMed: 22012633]
7. Takei H, Rouah E, Ishida Y. Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications. *Brain Tumor Pathol*. 2016; 33(1):1–12. [PubMed: 26496727]
8. Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, et al. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). *Int J Radiat Oncol Biol Phys*. 2017; 99(4):812–16. [PubMed: 29063850]
9. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). *JAMA Oncol*. 2017; 3(6):827–31. [PubMed: 27892978]
10. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. *Int J Radiat Oncol Biol Phys*. 2010; 77(3):655–61. [PubMed: 19942357]
11. Siam L, Bleckmann A, Chaung HN, Mohr A, Klemm F, Barrantes-Freer A, et al. The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study. *Oncotarget*. 2015; 6(30):29254–67. [PubMed: 26299612]
12. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. *Nature*. 2009; 459(7249):1005–9. [PubMed: 19421193]
13. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer discovery*. 2015; 5(11):1164–77. [PubMed: 26410082]
14. Erez N, Coussens LM. Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. *Int J Cancer*. 2011; 128(11):2536–44. [PubMed: 21387299]
15. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell*. 2012; 21(3):309–22. [PubMed: 22439926]
16. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer*. 2009; 9(4): 239–52. [PubMed: 19279573]
17. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer*. 2009; 9(4):274–84. [PubMed: 19308067]
18. Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B. Neocortical glial cell numbers in human brains. *Neurobiol Aging*. 2008; 29(11):1754–62. [PubMed: 17544173]
19. Fitch MT, Silver J. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. *Exp Neurol*. 2008; 209(2):294–301. [PubMed: 17617407]
20. Stiles J, Jernigan TL. The basics of brain development. *Neuropsychol Rev*. 2010; 20(4):327–48. [PubMed: 21042938]
21. Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. *Neuron*. 2008; 60(3):430–40. [PubMed: 18995817]
22. Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. *Acta Neuropathol*. 2010; 119(1): 37–53. [PubMed: 19847447]
23. Kimelberg HK, Nedergaard M. Functions of astrocytes and their potential as therapeutic targets. *Neurotherapeutics*. 2010; 7(4):338–53. [PubMed: 20880499]
24. Tay TL, Savage J, Hui CW, Bisht K, Tremblay ME. Microglia across the lifespan: from origin to function in brain development, plasticity and cognition. *J Physiol*. 2016

25. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. *Nat Rev Cancer*. 2011; 11(5):352–63. [PubMed: 21472002]
26. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, et al. Capillary pericytes regulate cerebral blood flow in health and disease. *Nature*. 2014; 508(7494):55–60. [PubMed: 24670647]
27. Dore-Duffy P. Pericytes: pluripotent cells of the blood brain barrier. *Curr Pharm Des*. 2008; 14(16): 1581–93. [PubMed: 18673199]
28. Del Bigio MR. Ependymal cells: biology and pathology. *Acta Neuropathol*. 2010; 119(1):55–73. [PubMed: 20024659]
29. Shechter R, London A, Schwartz M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. *Nat Rev Immunol*. 2013; 13(3):206–18. [PubMed: 23435332]
30. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. *J Clin Invest*. 2010; 120(5):1368–79. [PubMed: 20440079]
31. Raposo C, Graubardt N, Cohen M, Eitan C, London A, Berkutzi T, et al. CNS repair requires both effector and regulatory T cells with distinct temporal and spatial profiles. *J Neurosci*. 2014; 34(31): 10141–55. [PubMed: 25080578]
32. Schwartz M, Raposo C. Protective Autoimmunity: A Unifying Model for the Immune Network Involved in CNS Repair. *Neuroscientist*. 2014; 20(4):343–58. [PubMed: 24395337]
33. Pedemonte E, Mancardi G, Giunti D, Corcione A, Benvenuto F, Pistoia V, et al. Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. *Pharmacol Ther*. 2006; 111(3):555–66. [PubMed: 16442633]
34. Daphu I, Sundstrom T, Horn S, Huszthy PC, Niclou SP, Sakariassen PO, et al. In vivo animal models for studying brain metastasis: value and limitations. *Clin Exp Metastasis*. 2013; 30(5):695–710. [PubMed: 23322381]
35. Damsky WE Jr, Bosenberg M. Mouse melanoma models and cell lines. *Pigment Cell Melanoma Res*. 2010; 23(6):853–9. [PubMed: 20973935]
36. Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives. *Nat Rev Cancer*. 2017; 17(12):751–65. [PubMed: 29077691]
37. Schwartz H, Blacher E, Amer M, Livneh N, Abramovitz L, Klein A, et al. Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation. *Cancer Res*. 2016; 76(15):4359–71. [PubMed: 27261506]
38. Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M, et al. The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis. *Int J Cancer*. 2012; 131(5):1071–82. [PubMed: 22025079]
39. Cruz-Munoz W, Man S, Xu P, Kerbel RS. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. *Cancer Res*. 2008; 68(12):4500–5. [PubMed: 18559492]
40. Mathieu A, Rummelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, et al. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogeneity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. *Cancer*. 2004; 101(8):1908–18. [PubMed: 15386340]
41. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. *Cancer Res*. 1998; 58(7):1486–93. [PubMed: 9537252]
42. Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB, Kern FG. Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. *Cancer Res*. 1993; 53(9):2178–87. [PubMed: 8481921]
43. Puchalapalli M, Zeng X, Mu L, Anderson A, Hix Glickman L, Zhang M, et al. NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice. *PLoS One*. 2016; 11(9):e0163521. [PubMed: 27662655]

44. Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. *Nat Med.* 2016; 22(7):723–6. [PubMed: 27270588]
45. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. *Nat Neurosci.* 2007; 10(11):1387–94. [PubMed: 17965659]
46. O'Callaghan JP, Sriram K, Miller DB. Defining "neuroinflammation". *Ann N Y Acad Sci.* 2008; 1139:318–30. [PubMed: 18991877]
47. Gyoneva S, Ransohoff RM. Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines. *Trends Pharmacol Sci.* 2015; 36(7): 471–80. [PubMed: 25979813]
48. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. *J Neurochem.* 2002; 82(6):1311–29. [PubMed: 12354279]
49. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. *Nat Rev Neurosci.* 2017; 18(7):419–34. [PubMed: 28515434]
50. Guo S, Lo EH. Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. *Stroke.* 2009; 40(3 Suppl):S4–7. [PubMed: 19064781]
51. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. *Nat Rev Immunol.* 2015; 15(9):545–58. [PubMed: 26250739]
52. Quail DF, Joyce JA. The Microenvironmental Landscape of Brain Tumors. *Cancer Cell.* 2017; 31(3):326–41. [PubMed: 28292436]
53. Wilhelm I, Molnar J, Fazakas C, Hasko J, Krizbai IA. Role of the blood-brain barrier in the formation of brain metastases. *Int J Mol Sci.* 2013; 14(1):1383–411. [PubMed: 23344048]
54. Placone AL, Quinones-Hinojosa A, Searson PC. The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment. *Tumour Biol.* 2016; 37(1):61–9. [PubMed: 26493995]
55. Soto MS, Serres S, Anthony DC, Sibson NR. Functional role of endothelial adhesion molecules in the early stages of brain metastasis. *Neuro-oncology.* 2014; 16(4):540–51. [PubMed: 24311639]
56. Steeg PS. Targeting metastasis. *Nature reviews Cancer.* 2016; 16(4):201–18. [PubMed: 27009393]
57. Berghoff AS, Lassmann H, Preusser M, Hoftberger R. Characterization of the inflammatory response to solid cancer metastases in the human brain. *Clin Exp Metastasis.* 2013; 30(1):69–81. [PubMed: 22752508]
58. Berghoff AS, Preusser M. The inflammatory microenvironment in brain metastases: potential treatment target? *Chin Clin Oncol.* 2015; 4(2):21. [PubMed: 26112807]
59. Fidler IJ, Balasubramanian K, Lin Q, Kim SW, Kim SJ. The brain microenvironment and cancer metastasis. *Mol Cells.* 2010; 30(2):93–8. [PubMed: 20799011]
60. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, et al. Genomic analysis of reactive astrogliosis. *J Neurosci.* 2012; 32(18):6391–410. [PubMed: 22553043]
61. Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and disease. *Neuron.* 2014; 81(2):229–48. [PubMed: 24462092]
62. Liu Z, Chopp M. Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. *Prog Neurobiol.* 2016; 144:103–20. [PubMed: 26455456]
63. Lorgier M. Tumor microenvironment in the brain. *Cancers (Basel).* 2012; 4(1):218–43. [PubMed: 24213237]
64. Seike T, Fujita K, Yamakawa Y, Kido MA, Takiguchi S, Teramoto N, et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. *Clin Exp Metastasis.* 2011; 28(1):13–25. [PubMed: 20953899]
65. Klein A, Schwartz H, Sagi-Assif O, Meshel T, Izraely S, Ben Menachem S, et al. Astrocytes facilitate melanoma brain metastasis via secretion of IL-23. *J Pathol.* 2015; 236(1):116–27. [PubMed: 25639230]

66. Constantinescu CS, Tani M, Ransohoff RM, Wysocka M, Hilliard B, Fujioka T, et al. Astrocytes as antigen-presenting cells: expression of IL-12/IL-23. *J Neurochem.* 2005; 95(2):331–40. [PubMed: 16086689]
67. Xing F, Kobayashi A, Okuda H, Watabe M, Pai SK, Pandey PR, et al. Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. *EMBO Mol Med.* 2013; 5(3):384–96. [PubMed: 23495140]
68. Wu K, Fukuda K, Xing F, Zhang Y, Sharma S, Liu Y, et al. Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer. *The Journal of biological chemistry.* 2015; 290(15):9842–54. [PubMed: 25691572]
69. Xia MQ, Bacskaï BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. *J Neuroimmunol.* 2000; 108(1–2):227–35. [PubMed: 10900358]
70. Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. *J Leukoc Biol.* 2006; 79(3):596–610. [PubMed: 16365156]
71. Zubrilov I, Sagi-Assif O, Izraely S, Meshel T, Ben-Menahem S, Ginat R, et al. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. *Cancer Lett.* 2015; 361(1):86–96. [PubMed: 25725450]
72. Neman J, Choy C, Kowolik CM, Anderson A, Duenas VJ, Waliany S, et al. Co-evolution of breast-to-brain metastasis and neural progenitor cells. *Clin Exp Metastasis.* 2013; 30(6):753–68. [PubMed: 23456474]
73. Valiente M, Obenaus AC, Jin X, Chen Q, Zhang XH, Lee DJ, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. *Cell.* 2014; 156(5):1002–16. [PubMed: 24581498]
74. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. *Clin Exp Metastasis.* 2008; 25(7):799–810. [PubMed: 18649117]
75. Lorgier M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. *Am J Pathol.* 2010; 176(6):2958–71. [PubMed: 20382702]
76. Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A, et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. *Nature.* 2016; 533(7604):493–8. [PubMed: 27225120]
77. Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, et al. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. *Neoplasia.* 2011; 13(3):286–98. [PubMed: 21390191]
78. Stoletov K, Strnadel J, Zardoujian E, Momiyama M, Park FD, Kelber JA, et al. Role of connexins in metastatic breast cancer and melanoma brain colonization. *J Cell Sci.* 2013; 126(Pt 4):904–13. [PubMed: 23321642]
79. Jandial R, Choy C, Levy DM, Chen MY, Ansari KI. Astrocyte-induced Reelin expression drives proliferation of Her2+ breast cancer metastases. *Clin Exp Metastasis.* 2017; 34(2):185–96. [PubMed: 28210910]
80. Kim SW, Choi HJ, Lee HJ, He J, Wu Q, Langley RR, et al. Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. *Neuro Oncol.* 2014; 16(12):1585–98. [PubMed: 25008093]
81. Lee HJ, Hanibuchi M, Kim SJ, Yu H, Kim MS, He J, et al. Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. *Neuro Oncol.* 2016; 18(4):486–96. [PubMed: 26995790]
82. Chuang HN, van Rossum D, Sieger D, Siam L, Klemm F, Bleckmann A, et al. Carcinoma cells misuse the host tissue damage response to invade the brain. *Glia.* 2013; 61(8):1331–46. [PubMed: 23832647]
83. He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay BH, et al. Differential reactions of microglia to brain metastasis of lung cancer. *Mol Med.* 2006; 12(7–8):161–70. [PubMed: 17088948]

84. Andreou KE, Soto MS, Allen D, Economopoulos V, de Bernardi A, Larkin JR, et al. Anti-inflammatory Microglia/Macrophages As a Potential Therapeutic Target in Brain Metastasis. *Front Oncol.* 2017; 7:251. [PubMed: 29164051]
85. Amit M, Laider-Trejo L, Shalom V, Shabtay-Orbach A, Krelin Y, Gil Z. Characterization of the melanoma brain metastatic niche in mice and humans. *Cancer Med.* 2013; 2(2):155–63. [PubMed: 23634283]
86. Yousuf MA, Tan C, Torres-Altoro MI, Lu FM, Plautz E, Zhang S, et al. Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury. *J Neurochem.* 2016; 138(2):317–27. [PubMed: 26998748]
87. Song GJ, Jung M, Kim JH, Park H, Rahman MH, Zhang S, et al. A novel role for protein tyrosine phosphatase 1B as a positive regulator of neuroinflammation. *J Neuroinflammation.* 2016; 13(1): 86. [PubMed: 27095436]
88. Pukrop T, Dehghani F, Chuang HN, Lohaus R, Bayanga K, Heermann S, et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. *Glia.* 2010; 58(12): 1477–89. [PubMed: 20549749]
89. Rietkotter E, Bleckmann A, Bayerlova M, Menck K, Chuang HN, Wenske B, et al. Anti-CSF-1 treatment is effective to prevent carcinoma invasion induced by monocyte-derived cells but scarcely by microglia. *Oncotarget.* 2015; 6(17):15482–93. [PubMed: 26098772]
90. Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3Kgamma is a molecular switch that controls immune suppression. *Nature.* 2016; 539(7629):437–42. [PubMed: 27642729]
91. Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF, et al. Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. *Cell Rep.* 2016; 17(9):2445–59. [PubMed: 27840052]
92. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. *Nat Med.* 2013; 19(10): 1264–72. [PubMed: 24056773]
93. Moshe A, Izraely S, Sagi-Assif O, Prakash R, Telerman A, Meshel T, et al. Cystatin C takes part in melanoma-microglia cross-talk: possible implications for brain metastasis. *Clin Exp Metastasis.* 2018
94. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. *Nature.* 2015; 527(7576): 100–4. [PubMed: 26479035]
95. von Bernhardt R, Ramirez G. Microglia-astrocyte interaction in Alzheimer's disease: friends or foes for the nervous system? *Biol Res.* 2001; 34(2):123–8. [PubMed: 11715204]
96. Kavanagh E, Burguillos MA, Carrillo-Jimenez A, Oliva-Martin MJ, Santiago M, Rodhe J, et al. Deletion of caspase-8 in mouse myeloid cells blocks microglia pro-inflammatory activation and confers protection in MPTP neurodegeneration model. *Aging (Albany NY).* 2015; 7(9):673–89. [PubMed: 26405176]
97. Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. *Nat Cell Biol.* 2014; 16(9):876–88. [PubMed: 25086747]
98. Rippaus N, Taggart D, Williams J, Andreou T, Wurdak H, Wronski K, et al. Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases. *Oncotarget.* 2016; 7(27): 41473–87. [PubMed: 27203741]
99. Sugihara AQ, Rolle CE, Lesniak MS. Regulatory T cells actively infiltrate metastatic brain tumors. *Int J Oncol.* 2009; 34(6):1533–40. [PubMed: 19424570]
100. Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. *Oncoimmunology.* 2016; 5(1):e1057388. [PubMed: 26942067]
101. Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, et al. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking. *Proc Natl Acad Sci U S A.* 2018; 115(7):E1540–E49. [PubMed: 29386395]

102. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. *Semin Immunopathol.* 2009; 31(4):497–511. [PubMed: 19779720]
103. Shechter R, Miller O, Yovel G, Rosenzweig N, London A, Ruckh J, et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. *Immunity.* 2013; 38(3):555–69. [PubMed: 23477737]
104. Bechmann I, Steiner B, Gimsa U, Mor G, Wolf S, Beyer M, et al. Astrocyte-induced T cell elimination is CD95 ligand dependent. *J Neuroimmunol.* 2002; 132(1–2):60–5. [PubMed: 12417434]
105. Carbonell WS, Ansorge O, Sibson N, Muschel R. The vascular basement membrane as "soil" in brain metastasis. *PLoS One.* 2009; 4(6):e5857. [PubMed: 19516901]
106. Bentolila LA, Prakash R, Mihic-Probst D, Wadehra M, Kleinman HK, Carmichael TS, et al. Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways. *Sci Rep.* 2016; 6
107. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. *Nat Med.* 2010; 16(1):116–22. [PubMed: 20023634]
108. Murrell DH, Foster PJ, Chambers AF. Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications. *J Mol Med (Berl).* 2014; 92(1):5–12. [PubMed: 24306136]
109. Winkler F. Hostile takeover: how tumours hijack pre-existing vascular environments to thrive. *J Pathol.* 2017; 242(3):267–72. [PubMed: 28390068]
110. Xing F, Liu Y, Sharma S, Wu K, Chan MD, Lo HW, et al. Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. *Cancer Res.* 2016; 76(17):4970–80. [PubMed: 27364556]
111. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. *Clin Cancer Res.* 2010; 16(23):5664–78. [PubMed: 20829328]
112. Murrell DH, Hamilton AM, Mallett CL, van Gorkum R, Chambers AF, Foster PJ. Understanding Heterogeneity and Permeability of Brain Metastases in Murine Models of HER2-Positive Breast Cancer Through Magnetic Resonance Imaging: Implications for Detection and Therapy. *Transl Oncol.* 2015; 8(3):176–84. [PubMed: 26055175]
113. Osswald M, Blaas J, Liao Y, Solecki G, Gommel M, Berghoff AS, et al. Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases. *Clin Cancer Res.* 2016; 22(24):6078–87. [PubMed: 27521448]
114. Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, et al. Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer. *Clin Cancer Res.* 2016; 22(21):5287–99. [PubMed: 27245829]
115. Mittapalli RK, Adkins CE, Bohn KA, Mohammad AS, Lockman JA, Lockman PR. Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors. *Cancer Res.* 2017; 77(2):238–46. [PubMed: 27815391]
116. Liu T, Miao Z, Jiang J, Yuan S, Fang W, Li B, et al. Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2. *Int J Mol Sci.* 2015; 16(5):11439–51. [PubMed: 25993304]
117. Rodriguez PL, Jiang S, Fu Y, Avraham S, Avraham HK. The proinflammatory peptide substance P promotes blood-brain barrier breaching by breast cancer cells through changes in microvascular endothelial cell tight junctions. *Int J Cancer.* 2014; 134(5):1034–44. [PubMed: 23934616]
118. Lee HT, Xue J, Chou PC, Zhou A, Yang P, Conrad CA, et al. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. *Oncotarget.* 2015; 6(12):10016–29. [PubMed: 25881542]
119. Connell JJ, Chatain G, Cornelissen B, Vallis KA, Hamilton A, Seymour L, et al. Selective permeabilization of the blood-brain barrier at sites of metastasis. *J Natl Cancer Inst.* 2013; 105(21):1634–43. [PubMed: 24108809]

120. Zeng YD, Liao H, Qin T, Zhang L, Wei WD, Liang JZ, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy. *Oncotarget*. 2015; 6(10):8366–76. [PubMed: 25788260]
121. Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. *Neoplasia*. 2010; 12(9):748–54. [PubMed: 20824051]
122. Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. *Proc Natl Acad Sci U S A*. 2012; 109(45):E3119–27. [PubMed: 23071298]
123. Levy C, Allouache D, Lacroix J, Dugue AE, Supiot S, Campone M, et al. REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. *Ann Oncol*. 2014; 25(12):2351–6. [PubMed: 25274615]
124. Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, et al. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. *Clin Cancer Res*. 2015; 21(20):4630–41. [PubMed: 26106074]
125. Owonikoko TK, Arbiser J, Zelnak A, Shu HK, Shim H, Robin AM, et al. Current approaches to the treatment of metastatic brain tumours. *Nat Rev Clin Oncol*. 2014; 11(4):203–22. [PubMed: 24569448]
126. Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D, Jain RK. Emerging strategies for treating brain metastases from breast cancer. *Cancer Cell*. 2015; 27(2):163–75. [PubMed: 25670078]
127. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science*. 2015; 348(6230):56–61. [PubMed: 25838373]
128. Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. *BMC Med*. 2016; 14:20. [PubMed: 26850630]
129. Duchnowska R, Peksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B, et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. *Breast cancer research : BCR*. 2016; 18(1):43. [PubMed: 27117582]
130. Berghoff AS, Ricken G, Widhalm G, Rajky O, Dieckmann K, Birner P, et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases. *Histopathology*. 2015; 66(2):289–99. [PubMed: 25314639]
131. Melero-Jerez C, Ortega MC, Moline-Velazquez V, Clemente D. Myeloid derived suppressor cells in inflammatory conditions of the central nervous system. *Biochim Biophys Acta*. 2016; 1862(3):368–80. [PubMed: 26527182]
132. Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hambardzumyan D, Finke JH, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. *J Neurooncol*. 2015; 122(2):293–301. [PubMed: 25579983]
133. Kamran N, Candolfi M, Baker GJ, Ayala MM, Dzaman M, Lowenstein PR, et al. Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. *Methods Mol Biol*. 2016; 1382:467–82. [PubMed: 26611605]
134. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, et al. Premetastatic soil and prevention of breast cancer brain metastasis. *Neuro Oncol*. 2013; 15(7):891–903. [PubMed: 23595625]
135. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncol*. 2012; 13(5):459–65. [PubMed: 22456429]
136. Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S. Evolving treatment options for melanoma brain metastases. *Lancet Oncol*. 2015; 16(13):e486–97. [PubMed: 26433822]
137. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. *Lancet Oncol*. 2016; 17(7):976–83. [PubMed: 27267608]

138. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol.* 2018; 19(5):672–81. [PubMed: 29602646]
139. Queirolo P, Spagnolo F, Ascierto PA, Simeone E, Marchetti P, Scoppola A, et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. *J Neurooncol.* 2014; 118(1):109–16. [PubMed: 24532241]
140. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *N Engl J Med.* 2018; 379(8):722–30. [PubMed: 30134131]
141. Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M. Immune Checkpoint Inhibitors for Brain Metastases. *Curr Oncol Rep.* 2017; 19(6):38. [PubMed: 28417311]
142. D'Souza NM, Fang P, Logan J, Yang J, Jiang W, Li J. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. *Front Oncol.* 2016; 6:212. [PubMed: 27774435]
143. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. *J Clin Invest.* 2014; 124(2):687–95. [PubMed: 24382348]
144. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature.* 2015; 520(7547):373–7. [PubMed: 25754329]
145. Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. *Cell Stem Cell.* 2014; 14(3):306–21. [PubMed: 24607405]
146. Zakaria R, Das K, Bhojak M, Radon M, Walker C, Jenkinson MD. The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis. *Cancer Imaging.* 2014; 14:8. [PubMed: 25608557]
147. Cox GM, Kithcart AP, Pitt D, Guan Z, Alexander J, Williams JL, et al. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation. *J Immunol.* 2013; 191(3):1043–54. [PubMed: 23797673]
148. Shabab T, Khanabdali R, Moghadamtousi SZ, Kadir HA, Mohan G. Neuroinflammation pathways: a general review. *Int J Neurosci.* 2017; 127(7):624–33. [PubMed: 27412492]
149. Mehra A, Ali C, Parcq J, Vivien D, Docagne F. The plasminogen activation system in neuroinflammation. *Biochimica et biophysica acta.* 2016; 1862(3):395–402. [PubMed: 26493446]
150. Thompson WL, Van Eldik LJ. Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. *Brain research.* 2009; 1287:47–57. [PubMed: 19577550]
151. Konnecke H, Bechmann I. The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. *Clin Dev Immunol.* 2013; 2013
152. Wang L, Cossette SM, Rarick KR, Gershan J, Dwinell MB, Harder DR, et al. Astrocytes directly influence tumor cell invasion and metastasis in vivo. *PLoS One.* 2013; 8(12):e80933. [PubMed: 24324647]
153. Cai Z, Zhao B, Deng Y, Shanguan S, Zhou F, Zhou W, et al. Notch signaling in cerebrovascular diseases (Review). *Mol Med Rep.* 2016; 14(4):2883–98. [PubMed: 27574001]
154. Lee S, Kim JH, Kim JH, Seo JW, Han HS, Lee WH, et al. Lipocalin-2 Is a chemokine inducer in the central nervous system: role of chemokine ligand 10 (CXCL10) in lipocalin-2-induced cell migration. *The Journal of biological chemistry.* 2011; 286(51):43855–70. [PubMed: 22030398]
155. Kielian T. Glial connexins and gap junctions in CNS inflammation and disease. *Journal of neurochemistry.* 2008; 106(3):1000–16. [PubMed: 18410504]
156. D'Haeseleer M, Beelen R, Fierens Y, Cambron M, Vanbinst AM, Verborgh C, et al. Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. *Proceedings of the National Academy of Sciences of the United States of America.* 2013; 110(14):5654–8. [PubMed: 23509249]
157. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. *Cell.* 2010; 140(6):918–34. [PubMed: 20303880]

158. Vallee A, Vallee JN, Guillevin R, Lecarpentier Y. Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis. *Cell Mol Neurobiol*. 2018; 38(4):783–95. [PubMed: 28905149]
159. Walker DG, Tang TM, Lue LF. Studies on Colony Stimulating Factor Receptor-1 and Ligands Colony Stimulating Factor-1 and Interleukin-34 in Alzheimer's Disease Brains and Human Microglia. *Front Aging Neurosci*. 2017; 9:244. [PubMed: 28848420]
160. Cherry JD, Olschowka JA, O'Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. *Journal of neuroinflammation*. 2014; 11:98. [PubMed: 24889886]
161. Mammana S, Fagone P, Cavalli E, Basile MS, Petralia MC, Nicoletti F, et al. The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets. *International journal of molecular sciences*. 2018; 19(3)
162. Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. *Nature medicine*. 2016; 22(2):135–7.
163. Benkhoucha M, Santiago-Raber ML, Schnitzer G, Chofflon M, Funakoshi H, Nakamura T, et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107(14):6424–9. [PubMed: 20332205]
164. Chen E, Xu D, Lan X, Jia B, Sun L, Zheng JC, et al. A novel role of the STAT3 pathway in brain inflammation-induced human neural progenitor cell differentiation. *Curr Mol Med*. 2013; 13(9): 1474–84. [PubMed: 23971732]
165. Garcia AD, Doan NB, Imura T, Bush TG, Sofroniew MV. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. *Nature neuroscience*. 2004; 7(11):1233–41. [PubMed: 15494728]
166. Kuzmanovic M, Dudley VJ, Sarthy VP. GFAP promoter drives Muller cell-specific expression in transgenic mice. *Investigative ophthalmology & visual science*. 2003; 44(8):3606–13. [PubMed: 12882814]
167. Yona S, Kim KW, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity*. 2013; 38(1):79–91. [PubMed: 23273845]
168. Gerl K, Miquero L, Todorov VT, Hugo CP, Adams RH, Kurtz A, et al. Inducible glomerular erythropoietin production in the adult kidney. *Kidney international*. 2015; 88(6):1345–55. [PubMed: 26398496]
169. Zomer A, Maynard C, Verweij FJ, Kamermans A, Schafer R, Beerling E, et al. In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. *Cell*. 2015; 161(5): 1046–57. [PubMed: 26000481]
170. Christensen TD, Spindler KL, Palshof JA, Nielsen DL. Systematic review: brain metastases from colorectal cancer--Incidence and patient characteristics. *BMC Cancer*. 2016; 16:260. [PubMed: 27037031]
171. Goulart CR, Mattei TA, Ramina R. Cerebral melanoma metastases: a critical review on diagnostic methods and therapeutic options. *ISRN Surg*. 2011; 2011
172. Wyler L, Napoli CU, Ingold B, Sulser T, Heikenwalder M, Schraml P, et al. Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. *Br J Cancer*. 2014; 110(3):686–94. [PubMed: 24327013]

Box 1**Physiological roles of the different brain cells**

- ◆ *Neurons* are the excitable component of the CNS, their axons conduct electrical current. The development and specialization of neurons during embryogenesis is a very complex and temporally regulated process (20).
- ◆ *Oligodendrocytes* produce myelin, which is essential for proper electric conduction of neuronal signaling (21,22).
- ◆ *Astrocytes* have many functional roles in maintaining brain homeostasis: they regulate potassium and pH levels, modulate synaptic transmission by glutamate and GABA uptake, and control the vascular tone and cerebral blood flow (23). Two main classes of astrocytes include protoplasmic astrocytes residing within the gray matter, and fibrous astrocytes located in the white matter (21).
- ◆ *Microglia* are specialized resident macrophages in the brain, which originate in the yolk sac. Microglia secrete growth factors and inflammatory mediators, and scavenge cell debris and is involved in the CNS homeostasis (24).
- ◆ *Endothelial cells* and their extracellular matrix form the blood vessels of the brain. Endothelial cells express efflux pumps and establish adjacent tight junctions, both of which are necessary for selective permeability of the blood-brain barrier (BBB) (25).
- ◆ *Pericytes* are mesenchymal cells, which constitute an integral part of the neovascular unit of the BBB. Pericytes occur throughout the vasculature of the body, but are most dense in brain capillaries. Pericytes regulate cerebral blood flow (26), and produce proteins of the basal lamina (27).
- ◆ *Ependymal cells* line the ventricles of the brain and are part of the blood-cerebrospinal fluid (CSF) barrier (*BCSFB*) (28,29).
- ◆ *Choroid plexus* is a specialized organ within the brain which produces the CSF and is also part of the BCSFB (28).
- ◆ *Post-capillary Venules*: An important part of the BBB. Composed of at least seven layers: 1. Endothelial cells connected by tight junctions, 2. Inner basement membrane, 3. Media, 4. Outer basement membrane, 5. Virchow-Robin space with pericytes, macrophages and other cell types, 6. A third basement membrane 7. The glia limitans, consistent of astrocyte end-feet (See Figure 1B).
- ◆ *Blood-leptomeningeal barrier (BLMB)*: An important immunological barrier, typically activated during meningitis. Activation switches the cellular and molecular composition of the CSF from an immunosuppressive body-fluid to a highly immune active one.

- ◆ *Infiltrating immune cells* can be recruited to the brain via the BCSFB to the CSF or via the blood capillaries, mainly via post capillary venules (29,30). T cells and monocyte-derived macrophages contribute to neuronal functions and are central to neuronal repair (31,32) and during the brain response to pathogen invasion and inflammation (33).

Box 2**Murine models of brain metastasis to study the brain microenvironment and neuroinflammation****Models of spontaneous brain metastasis**

By definition, a spontaneous model of brain metastasis is a model in which cancerous cells from the primary tumor are allowed to detach, invade, circulate, extravasate and colonize the brain. The main advantage of utilizing such models is that they allow investigation of the different metastatic stages, as well as studying early stages of brain metastasis in a clinically relevant setting. However, most spontaneous models are time-consuming and do not always provide high percentages of brain metastasis, making large cohorts of mice necessary.

- ◆ The primary tumors in spontaneous models are either orthotopically inoculated or arise in a genetically engineered mouse model (GEMMs) of a certain cancer type. Brain metastasis in GEMMs was reviewed elsewhere (34,35).
- ◆ Resection of the primary tumor, when feasible, allows better modeling of the clinical settings, and usually entails a period of latency before metastatic relapse, thus enabling a time window for pre-clinical preventative studies (36).
- ◆ Spontaneous models of brain metastasis can be established in immunocompetent or in immunodeficient mice, depending on the source of the cells to be studied.

Summary of murine models of spontaneous brain metastasis

- **Melanoma:**
 - RMS: Orthotopic (subdermal), immunocompetent, primary tumor removal. Micrometastases 50%, Macrometastases 23% (37).
 - YDFR.CB3: Orthotopic (subdermal), immunodeficient, Micrometastases 75% (38).
 - 131/4-5B2: Orthotopic (subdermal), immunodeficient, primary tumor removal. Micrometastases 66%, Macrometastases 20% (39).
- **Lung**
 - A549: Orthotopic (intrathoracic), immunodeficient. Macrometastases 61% (40).
- **Breast**
 - 4T1: Orthotopic (intraductal), immunocompetent, primary tumor removal, Micrometastasis 67% (41).
 - Fgf4-MCF7: Orthotopic (intraductal), immunodeficient, Macrometastases 35% (42).

- MDA-MB-231 and CN34BrM: Orthotopic (bilateral intraductal), immunodeficient, NSG mice, Macrometastases 100%, 90% respectively (43).

Models of experimental brain metastasis

Experimental metastasis models include the direct inoculation of tumor cells into the circulation, and provide a model for hematogenous dissemination of cancer cells to generate brain metastases.

- ◆ Intracardiac injection: inoculation of tumor cells into the left ventricle of the heart.
- ◆ Intracarotid injection: inoculation of the tumor cells directly into the cerebral circulation.

Experimental models are widely used, as they achieve a high penetrance of brain metastasis in relatively small cohorts of mice and are a valuable tool for studying macrometastases, especially in pre-clinical testing of therapeutic intervention.

Disadvantages of these models include the technically challenging nature of injection techniques, and the fact that the high load of injected cells may not accurately mimic the clinical settings in which metastasis occurs.

Models of intracranial tumor cell injections

Tumor cell growth in the brain can be achieved by intracranial injection: the direct inoculation of tumor cells from various cancer types directly into the brain tissue.

Intracranial models of brain metastasis can be established in immunocompetent or in immunodeficient mice, (including patient-derived xenografts, (PDX) (44)), depending on the source of the cells to be studied.

Intracranial injections yield rapidly growing brain lesions and are an important tool to assess the growth pattern of tumor cells in brain, the various infiltration types and dissemination into the brain parenchyma, and to test the efficacy of novel therapeutics in a pre-clinical setting of full blown macrometastasis. However, the injection of cells into the parenchyma may initially cause trauma to the brain, thus invoking astrogliosis and neuroinflammation. Therefore, when employing such models it is important to design suitable controls.

Figure 1.

A. Epidemiology of brain metastases. Summary of main epidemiological findings from various primary tumor types that metastasize to brain (%: percentage of brain metastasis cases diagnosed, m=months) (1,2,170–172). **B. The brain microenvironment:** Illustration of different cell types in normal brain. The physiological roles of different brain cells are detailed in Box 1.

Figure 2.
Reciprocal interactions between brain-metastasizing tumor cells and the brain microenvironment facilitate metastatic growth. Main findings of neuroinflammatory networks operative in brain metastasis.

Table 1
Concise summary of main findings and targetable molecules in neuroinflammation
instigated in brain metastasis.

Findings from pre-clinical studies in which targeting of neuroinflammation showed efficacy in the treatment of brain metastases, as well as targets that may be promising. ¹MMPs inhibitors, ²BBB permeable metalloproteinase inhibitor, ³A potent BBB permeable γ -secretase inhibitor, ⁴Gap junction inhibitor, ⁵Antagonists of ETAR and ETBR ⁶Bisphosphonate, ⁷c-MET inhibitor, ⁸STAT3 inhibitor.

Neuroinflammatory pathways or function found in brain metastasis	System	Targeted?	Ref	Neuroinflammatory pathways or function in CNS pathology	Ref
Proliferation of metastatic cells is mediated by Tumor cells secreted: MIF, IL-8 and PAI-1 Astrocytes to secreted: IL-1 β , TNF α and IL-6	<i>In vitro</i>	No	(64)	C/EBP- β NFkB	(147) (148,149)
Tumor cell invasion to the brain is regulated by Astrocyte-derived: IL-23 CCL7 MMP2 MMP9 Tumor-derived: MMP2 COX-2 MMP1	<i>In vitro</i> <i>In vivo</i>	Anti-IL-23 Ab. shCCL7 anti-MMP2 Ab., anti-MMP9 Ab. ONO-4817, Marimastat ¹ , Batimastat ¹ No shCOX2 shMMP1, GM6001 ²	(65) (68) (152) (152) (65) (68)	Antigen presentation MAPK, NFkB Leukocyte transmigration Neuronal damage	(66) (150) (151) (148)
CSC self-renewal is mediated by: JAG1-Notch-HES5 signaling in astrocytes IL-1 β secreted from tumor cells	<i>In vitro</i> <i>In vivo</i>	shHES5, shJAG1 shIL-1 β , Compound E ³	(67)	Notch	(153)
Activated astrocytes express gliosis related gene signature: <i>Cxcl10</i> , <i>Lcn2</i> , <i>Timp1</i> , <i>Serpine1</i>	<i>In vitro</i> <i>In vivo</i>	No	(37)	STAT3, NF- κ B	(154)
Astrocytes induce the expression of <i>Gsta5</i> , <i>Bcl2l1</i> , <i>Twist1</i> in tumor cells, leading to chemoresistance	<i>In vitro</i>	siRNA of survival genes	(77)	Gap-junction intercellular communication	(155)
Astrocytes activate the Endothelin axis in tumor cells, providing chemoprotection	<i>In vitro</i> <i>In vivo</i>	Carbenoxolone (CBX) ⁴ BQ123 ³ , BQ788 ⁵ Macitentan ⁵ + Paclitaxel	(80,81) (124)	Cap-junction intercellular communication ET-1 is a potent vasoconstrictor	(155) (156)
Gap junctions allow communication between tumor cells and astrocytes	<i>In vitro</i> <i>In vivo</i>	CBX shcGAS	(76)	Cap-junction intercellular	(155)
Initial anti-tumorigenic responses of astrocytes to metastasizing cells mediated via: FasL, plasminogen activator from astrocytes	<i>In vitro</i> <i>In vivo</i>	anti-FasL α 2-antiplasmin shNeuroserpin, shSerpineB2, shSerpineD2, shL1CAM	(73)	Tissue damage, Apoptosis	(157)

Neuroinflammatory pathways or function found in brain metastasis	System	Targeted?	Ref	Neuroinflammatory pathways or function in CNS pathology	Ref
Serpins from reactive stroma Tumor cells expressing L1CAM					
Microglia facilitate transport of cancer cells into the brain	<i>In vitro</i>	WNT-inhibitor Dickkopf-2 Clodronate ⁶	(88)	Wnt/ β -catenin	(158)
Microglia defense response is hijacked by carcinoma cells	<i>In vitro</i>	Anti-CSF-1 Ab. 5A1 Anti-CD34 Ab	(89)	Microglia survival and growth	(159)
Depletion of the anti-inflammatory microglia/macrophage cell population attenuate metastatic colonization	<i>In vivo</i>	Clodronate ⁶	(84)	M1 and M2 phenotypes of microglia/macrophage	(160)
Different phenotypes of metastasis-associated macrophages in dural vs parenchymal metastasis	<i>In vivo</i>	No	(98)	Macrophages are involved in neuroinflammation	(161)
NK cells and CD8+ T cells are required for efficient anti-PD-1/anti-CTLA-4 intracranial tumor response	<i>In vivo</i>	PD-1/CTLA-4 combined blockade	(101)	Immune checkpoints are possible therapeutic targets in AD	(162)
Adhesion and angiogenesis is mediated via: Tumor cell secreted IL-1 β , CXCL1, IL-18 Astrocyte-derived HGF Endothelial cells expressing CXCR1	<i>In vitro</i> <i>In vivo</i>	Pterostilbene ⁷	(110)	HGF attenuates autoimmunity in experimental autoimmune encephalitis (EAE)	(163)
STAT3 activation induces cancer cell-directed VEGF secretion $\rightarrow$ STAT3 activation in endothelial cells $\rightarrow$ upregulated VEGFR2 in endothelial cells	<i>In vitro</i> <i>In vivo</i>	WP1066 ⁸	(118)	STAT3	(164)

Table 2
Genetic tools to study the brain microenvironment and neuroinflammation in murine models.

Genetic tools are valuable in studying the reciprocal interactions between cancer cells and cells of the microenvironment. Combining these tools to create unique orthotopic spontaneous brain metastasis models of brain metastasis will facilitate the attainment of innovative functional experiments on mechanisms of pre-metastatic niche, screening of potential drugs, validation of diagnostic techniques etc.

Available strains	Enables the study of	Potential applications
GFAP-Cre/ER (165) GFAP-GFP (166) ALDH1L1-GFP (60)	Astrocytes	Knockdown of astrocyte-specific genes Isolating metastasis-associated astrocytes by FACS
CX3CR1-CRE (167) CX3CR1-CRE/ER (167) CX3CR1-GFP (167)	Microglia	Knockdown of microglia-specific genes Isolating metastasis-associated microglia by FACS
PDGFRb-Cre/ER (168)	Pericytes	Knockdown of pericyte-specific genes
Cre-LoxP System to Measure EV Uptake (169)	Tumor-derived exosomes	Studying exosomes in pre-metastatic niche